Carboplatin and Bevacizumab for Recurrent Ependymoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT01295944
Phase
PHASE2
Status
Completed

Conditions

  • Anaplastic Ependymoma
  • Ependymoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
  • Bevacizumab — DRUG
    Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.

Study Details

The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.

Key Dates

First listed
Feb 15, 2011
Start date
Apr 27, 2011
Status verified
Jul 2025
Primary completion
Sep 23, 2020
Completion
May 14, 2021

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1/Carboplatin and Bevacizumab for Recurrent Ependymoma
    The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician.

Primary Outcome Measure

Percentage of Participants That Have Progressive Free Survival (PFS) After 1 Year [ Time Frame: 1 year ]

Locations (2)

FacilityCityStateZIPSite coordinators
Massachusetts General Hospital/Dana FarberBostonMassachusetts02114-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10021-

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital/Dana Farber· Boston, MAMemorial Sloan Kettering Cancer Center· New York, NY

Related Studies